JPMorgan in the US has an "overweight" call on Mesoblast.
"Mesoblast reported a FY1Q16 per share loss of $0.04. While Mesoblast has a broad pipeline based on its proprietary mesenchymal lineage adult stem cells (MLCs), on the call, the company prudently focused on the MSC-100-IV program in paediatric acute graft versus host disease (aGVHD), a critical 2016 catalyst, in our view.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
